Bayer's Progress in Pharma and Biofuels Overshadowed as Supreme Court Poised to Decide Fate of Glyphosate Claims
14.06.2026 - 06:05:15 | boerse-global.de
The coming weeks will deliver a binary moment for Bayer that could either unlock substantial value or deepen the legal quagmire. While the German conglomerate has been steadily rebuilding its operational foundations and advancing its drug pipeline, the market’s focus remains locked on Washington, where the US Supreme Court is expected to rule in June on the pivotal glyphosate case “Durnell.” The outcome will determine the fate of more than 100,000 pending lawsuits and billions of euros in potential liabilities.
In the background, Bayer’s newest management team has been making tangible headway. Chief executive Bill Anderson has overhauled the leadership structure, with Judith Hartmann taking over as finance chief since the start of June and Jost Reinhard set to lead the radiology division from August. The changes are beginning to show. First?quarter 2026 revenue rose 4.1% on a currency?adjusted basis to €13.4bn, while adjusted EBITDA climbed to €4.45bn. More than 12,000 positions have already been cut globally as part of a restructuring programme that targets €2bn in sustainable cost savings by year?end.
Yet none of this operational momentum is being reflected in the share price. The stock closed last week at €36.06, trading just 0.21% above its 200?day moving average of €35.99 – a technical support line that chart watchers view as critical. The relative strength index stands at 45.3, pointing to complete indecision. Below the 50?day average of €38.10, the equity is trapped by the weight of legal uncertainty.
Should investors sell immediately? Or is it worth buying Bayer?
Positive developments in the pharmaceutical and agricultural units are equally failing to lift sentiment. On 11 June, the European Medicines Agency validated Bayer’s marketing application for Asundexian, a drug designed to prevent strokes in at?risk patients. The submission rests on the phase?III OCEANIC?STROKE study, which showed a 26% reduction in stroke risk without an increase in major bleeding. The clean safety profile could position Asundexian as a strong contender in the anticoagulant market. Separately, Bayer has accelerated its plans for camelina, an oilseed used as a feedstock for biodiesel and sustainable aviation fuel. A new partnership with BP aims to develop the North American market, and the company now expects to reach a million acres of camelina cultivation well before the mid?2030s, helped by contracts with mill operators that provide farmers with guaranteed offtake.
The financial picture remains strained, however. The group closed fiscal 2025 with a net loss of €3.62bn, and net financial debt at the end of that year stood at €29.84bn. By the end of the first quarter of 2026, debt had risen further to €32.5bn, driven by €2.32bn in negative free cash flow as large payouts for PCB and glyphosate settlements drained cash. Management now expects a full?year 2026 free cash flow of between minus €1.5bn and minus €2.5bn, with roughly €5bn earmarked for legal settlements alone.
The weight of the balance sheet and the court docket leaves little room for margin of error. Berenberg analysts assign a 60% probability of a favourable Supreme Court ruling for Bayer and maintain a “hold” rating with a price target of €40.50. That target would represent a roughly 12% upside from current levels, but it depends entirely on whether the court decides that glyphosate plaintiffs cannot sue over missing warning labels given that the Environmental Protection Agency deems the herbicide safe. During oral hearings, justices appeared split, with conservative Chief Justice Roberts and Justice Gorsuch joining liberal Justice Jackson in pressing Bayer with tough questions. A defeat would keep the litigation overhang alive and likely deepen the market’s aversion to the stock.
For now, the share price is effectively a call option on the Supreme Court. The operational turnaround and promising pipeline are real but cannot be fully priced in until the legal cloud clears. The decision, expected within weeks, will determine whether Bayer can finally pivot from defence to growth.
Ad
Bayer Stock: New Analysis - 14 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
